Is MESOBLAST LTD (MESO) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.1% / 30% | 7.7% / 30% | 0.7% / 30% | 20.67% / 5% | ✗ NOT HALAL |
| DJIM | 6.1% / 33% | 7.7% / 33% | 0.7% / 33% | 20.67% / 5% | ✗ NOT HALAL |
| MSCI | 16.3% / 33% | 20.5% / 33% | 1.9% / 33% | 20.67% / 5% | ✗ NOT HALAL |
| S&P | 6.1% / 33% | 7.7% / 33% | 0.7% / 33% | 20.67% / 5% | ✗ NOT HALAL |
| FTSE | 16.3% / 33% | 20.5% / 33% | 1.9% / 50% | 20.67% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -35.5% | |
| Operating Margin | -55.2% | |
| Net Margin | -144.3% | |
| Return on Equity (ROE) | -18.2% | |
| Return on Assets (ROA) | -6.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$50M |
| Free Cash Flow | -$51M |
| Total Debt | $128M |
| Debt-to-Equity | 23.5 |
| Current Ratio | 1.6 |
| Total Assets | $785M |
Price & Trading
| Last Close | $14.86 |
| 50-Day MA | $16.34 |
| 200-Day MA | $15.85 |
| Avg Volume | 233K |
| Beta | 0.8 |
|
52-Week Range
$9.61
| |
About MESOBLAST LTD (MESO)
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MESOBLAST LTD (MESO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MESOBLAST LTD is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MESOBLAST LTD's debt ratio?
MESOBLAST LTD's debt ratio is 6.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 16.3%.
What are MESOBLAST LTD's key financial metrics?
MESOBLAST LTD has a market capitalization of $1.9B, and revenue of $17M. The company maintains a gross margin of -35.5% and a net margin of -144.3%. Return on equity stands at -18.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.